Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer treatment reviews"
DOI: 10.1016/j.ctrv.2021.102178
Abstract: Non─small cell lung cancer (NSCLC) presents different druggable genetic abnormalities, including ROS1 and ALK rearrangements, which share relevant clinical features and therapeutic strategies. The homology between the tyrosine kinase domains of ROS1 and ALK defines… read more here.
Keywords: treatment; ros1 alk; non small; cancer ... See more keywords
Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
Sign Up to like & getrecommendations! Published in 2022 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noac087
Abstract: Abstract Background Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors and adults with ROS1 fusion-positive non–small-cell lung cancer.… read more here.
Keywords: rp2d; ros1 alk; phase; tumors harboring ... See more keywords
Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non–small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-17-2452
Abstract: Purpose: Despite initial benefit from tyrosine kinase inhibitors (TKIs), patients with advanced non–small cell lung cancer (NSCLC) harboring ALK (ALK+) and ROS1 (ROS1+) gene fusions ultimately progress. Here, we report on the potential resistance mechanisms… read more here.
Keywords: cancer; ros1 alk; resistance mechanisms; resistance ... See more keywords
Abstract CT030: STARTRK-NG: A phase 1/1b study of entrectinib in children and adolescents with advanced solid tumors and primary CNS tumors, with or without TRK, ROS1, or ALK fusions
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-ct030
Abstract: Background: The STARTRK-NG (Studies of Tumor Alterations Responsive to Targeting Receptor Kinases - Next Generation) trial is a Phase 1/1b dose-escalation and expansion study of entrectinib in pediatric patients with cancer. Entrectinib is a potent… read more here.
Keywords: trk ros1; phase; solid tumors; alk ... See more keywords
Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2021.788245
Abstract: Pemetrexed (used as a platinum doublet or as a maintenance regimen) is an established therapy for patients with advanced non-squamous non-small-cell lung cancer (NSCLC). In addition, certain gene rearrangements (e.g., ALK, ROS1, RET) appear to… read more here.
Keywords: therapy; histology; lung cancer; ros1 alk ... See more keywords